Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in somatotrophs | 0.75 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 5 Parkinson's papers of 64 | 0.76 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 6125
Sealed predictions
- CADPS in dopamine neurons, braak+0.38 (p 0.309) → +0.68 (p 0.042)receipt 6133
Swarm cases
receipt 6133: CADPS in dopamine neurons, braak
- power
- full sample +0.54 (p 0.021, n 18), 95% CI +0.10 to +0.80. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.52 (p 0.028, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.50 (p 0.033, n 18). not the mix.
- skeptic
- leave-one-out range +0.47 to +0.68, sign flips 0; without severely affected donors +0.54 (p 0.021, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CADPS in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts